Keywords: Teva, Laquinimod, Multiple sclerosis, Ph III
Mixed Phase III results for Teva’s MS drug laquinimod
Article | 02 August 2011
There were mixed but largely disappointing Phase III trial results for Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) regarding its experimental ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
